Campbell & CO Investment Adviser LLC Makes New $1.48 Million Investment in Kiniksa Pharmaceuticals International, plc $KNSA

Campbell & CO Investment Adviser LLC bought a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 38,117 shares of the company’s stock, valued at approximately $1,480,000. Campbell & CO Investment Adviser LLC owned approximately 0.05% of Kiniksa Pharmaceuticals International as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. EverSource Wealth Advisors LLC lifted its stake in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares during the period. Osaic Holdings Inc. purchased a new position in Kiniksa Pharmaceuticals International during the 2nd quarter valued at about $31,000. USA Financial Formulas bought a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at about $32,000. Quantbot Technologies LP purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth approximately $43,000. Finally, Farther Finance Advisors LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 582.4% during the third quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company’s stock valued at $53,000 after purchasing an additional 1,159 shares in the last quarter. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Stock Up 3.9%

KNSA stock opened at $39.41 on Friday. The stock has a market capitalization of $2.99 billion, a PE ratio of 87.58 and a beta of 0.04. Kiniksa Pharmaceuticals International, plc has a 52 week low of $18.12 and a 52 week high of $44.42. The firm has a 50 day moving average of $41.35 and a 200 day moving average of $36.75.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The company had revenue of $180.86 million for the quarter, compared to analyst estimates of $166.64 million. During the same quarter in the previous year, the company posted ($0.18) EPS. The company’s revenue for the quarter was up 61.2% compared to the same quarter last year. On average, equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on KNSA. Wedbush increased their target price on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. Citigroup boosted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, October 17th. TD Cowen assumed coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They set a “buy” rating and a $60.00 price target for the company. Finally, The Goldman Sachs Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of “Moderate Buy” and a consensus target price of $52.33.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 82,542 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Friday, October 31st. The stock was sold at an average price of $37.14, for a total transaction of $3,065,609.88. Following the completion of the sale, the insider owned 61,324 shares of the company’s stock, valued at approximately $2,277,573.36. The trade was a 57.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Mark Ragosa sold 42,841 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $41.49, for a total value of $1,777,473.09. Following the completion of the sale, the chief financial officer owned 31,086 shares in the company, valued at approximately $1,289,758.14. This represents a 57.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 510,689 shares of company stock worth $20,009,290 over the last three months. Corporate insiders own 53.48% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.